RxDoctor Payments Data

Nadavaluru Reddy, MD

Clinical Cardiac Electrophysiology · Springfield, MANPI 1689852691

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (48.5%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Biotronik Inc. at 36.8% of the total.

$69,167in general payments, 2019–2025

Across 594 payments — averaging $116.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotronik Inc.$25K
  • Abbott$19K
  • Medtronic$17K
  • Boston Scientific$2K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$2K
  • Biosense Webster, Inc.$1K
  • plus $3K from 10 others

What the payments were for

  • Consulting fees$8,62812%
  • Speaking & faculty fees$4,7007%
  • Travel & lodging$22,11832%
  • Food & beverage$33,54448%
  • Education$1770%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$69,167 in reported general payments places this provider in the 80th percentile of 106 clinical cardiac electrophysiology providers in Massachusetts.

See all clinical cardiac electrophysiology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$356,389
Medicare patients
1,485
Services billed
5,218

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban75$100,804
XareltoRivaroxaban16$25,261
EntrestoSacubitril/Valsartan24$22,667
Amiodarone Hcl48$2,988
Metoprolol Succinate78$1,521
Diltiazem 24hr Er (Cd)Diltiazem Hcl35$960
Flecainide Acetate15$805
ClopidogrelClopidogrel Bisulfate68$692
SotalolSotalol Hcl16$466
Losartan Potassium19$403
Atorvastatin Calcium32$403
Warfarin Sodium18$263
Lisinopril22$212
Metoprolol Tartrate43$207
Rosuvastatin Calcium11$181

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$556$100,80475 claims
Johnson & JohnsonXarelto$532$25,26116 claims
NovartisEntresto$359$22,66724 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 106 clinical cardiac electrophysiology providers in Massachusetts.

Other clinical cardiac electrophysiology in Springfield

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →